Abstract
Background: Lung-sparing cytoreductive surgery by extended pleurectomy and decortication (EPD) in combination with hyperthermic intrathoracic chemoperfusion (HITOC) forms a promising treatment strategy for malignant pleural mesothelioma and recurrent pleural thymic malignancies. Objectives: The objective of this study was to scrutinize the surgical procedure and perioperative patient management with emphasis on perioperative morbidity and local tumor control. Methods: In 2014, a standardized EPD and HITOC procedure was implemented at the Thoraxklinik Heidelberg. This retrospective analysis included clinical data of consecutive patients with pleural mesothelioma and pleural metastasized malignancies treated by EPD and HITOC. The surgical procedure, perioperative management, lung function data, and progression-free survival (PFS) were analyzed. Results: In the time range between April 2, 2014 and July 2018, 76 patients with pleural malignancies have been treated with EPD and HITOC, and were analyzed retrospectively. It included 61 patients with pleural mesothelioma and 15 patients with pleural metastases of thymic malignancies (12), non-small cell lung cancer (1), colorectal carcinoma (1), and sarcoma (1). Perioperative morbidity following EPD and HITOC treatments represented 23.7% of overall malignancies, while 30- and 90-day mortality were 0 and 1.3%, respectively. Median PFS lasted 18.4 months for mesothelioma and 72.2 months for thymic malignancies. Conclusion: Combining EPD with HITOC can be performed in patients with either pleural mesothelioma or pleural metastases resulting in low perioperative morbidity and mortality as well as remarkable local tumor control.
References
1.
Marx
A
, Chan
JK
, Coindre
JM
, Detterbeck
F
, Girard
N
, Harris
NL
, The 2015 World Health Organization classification of tumors of the thymus: continuity and changes
. J Thorac Oncol
. 2015
;10
(10
):1383
–95
. .2.
Do
YW
, Lee
HJ
, Narm
KS
, Jung
HS
, Lee
JG
, Kim
DJ
, Tumor perimeter and lobulation as predictors of pleural recurrence in patients with resected thymoma
. Lung Cancer
. 2016
;98
:79
–83
. .3.
Ambrogi
MC
, Korasidis
S
, Lucchi
M
, Fanucchi
O
, Giarratana
S
, Melfi
F
, Pleural recurrence of thymoma: surgical resection followed by hyperthermic intrathoracic perfusion chemotherapy
. Eur J Cardiothorac Surg
. 2016
;49
(1
):321
–6
.4.
Opitz
I
, Weder
W
. Pleural mesothelioma: is the surgeon still there?
Ann Oncol
. 2018
;29
(8
):1710
–7
. .5.
Taioli
E
, Wolf
AS
, Flores
RM
. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma
. Ann Thorac Surg
. 2015
;99
(2
):472
–80
. .6.
de Bree
E
, van Ruth
S
, Baas
P
, Rutgers
EJ
, van Zandwijk
N
, Witkamp
AJ
, Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma
. Chest
. 2002
;121
(2
):480
–7
. .7.
Sugarbaker
PH
. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
Lancet Oncol
. 2006
;7
(1
):69
–76
. .8.
Sugarbaker
DJ
, Gill
RR
, Yeap
BY
, Wolf
AS
, DaSilva
MC
, Baldini
EH
, Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection
. J Thorac Cardiovasc Surg
. 2013
;145
(4
):955
–63
. .9.
Friedberg
JS
, Culligan
MJ
, Tsao
AS
, Rusch
V
, Sepesi
B
, Pass
HI
, A proposed system toward standardizing surgical-based treatments for malignant pleural mesothelioma, from the joint National Cancer Institute-international association for the study of lung cancer-mesothelioma applied research foundation taskforce
. J Thorac Oncol
. 2019
;14
(8
):1343
–53
. .10.
Travis
WD
, Brambilla
E
, Burke
AP
, Marx
A
, Nicholson
AG
. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart
. J Thorac Oncol
. 2015
;10
(9
):1240
–2
. .11.
Scherpereel
A
, Astoul
P
, Baas
P
, Berghmans
T
, Clayson
H
, de Vuyst
P
, Guidelines of the european respiratory society and the european society of thoracic surgeons for the management of malignant pleural mesothelioma
. Eur Respir J
. 2010
;35
(3
):479
–95
. .12.
Klotz
LV
, Lindner
M
, Eichhorn
ME
, Grützner
U
, Koch
I
, Winter
H
, Pleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma
. J Thorac Dis
. 2019
;11
(5
):1963
–72
. .13.
van Gerwen
M
, Wolf
A
, Liu
B
, Flores
R
, Taioli
E
. Short-term outcomes of pleurectomy decortication and extrapleural pneumonectomy in mesothelioma
. J Surg Oncol
. 2018
;118
(7
):1178
–87
. .14.
Elias
D
, Raynard
B
, Boige
V
, Laplanche
A
, Estphan
G
, Malka
D
, Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis
. J Surg Oncol
. 2005
;90
(4
):220
–5
. .15.
Weber
RS
, Jabbour
N
, Martin
RC
2nd. Anemia and transfusions in patients undergoing surgery for cancer
. Ann Surg Oncol
. 2008
;15
(1
):34
–45
. .16.
Saxena
A
, Chua
TC
, Fransi
S
, Liauw
W
, Morris
DL
. Effectiveness of early and aggressive administration of fresh frozen plasma to reduce massive blood transfusion during cytoreductive surgery
. J Gastrointest Oncol
. 2013
;4
(1
):30
–9
. .17.
Preti
V
, Chang
D
, Sugarbaker
PH
. Pulmonary complications following cytoreductive surgery and perioperative chemotherapy in 147 consecutive patients
. Gastroenterol Res Pract
. 2012
;2012
:635314
. .18.
Bell
JC
, Rylah
BG
, Chambers
RW
, Peet
H
, Mohamed
F
, Moran
BJ
. Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: a multi-institutional experience
. Ann Surg Oncol
. 2012
;19
(13
):4244
–51
. .19.
Sargant
N
, Roy
A
, Simpson
S
, Chandrakumaran
K
, Alves
S
, Coakes
J
, A protocol for management of blood loss in surgical treatment of peritoneal malignancy by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
. Transfus Med
. 2016
;26
(2
):118
–22
. .20.
Ratto
GB
, Civalleri
D
, Esposito
M
, Spessa
E
, Alloisio
A
, De Cian
F
, Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study
. J Thorac Cardiovasc Surg
. 1999
;117
(4
):759
–65
. .21.
van Ruth
S
, van Tellingen
O
, Korse
CM
, Verwaal
VJ
, Zoetmulder
FA
. Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma
. Anticancer Drugs
. 2003
;14
(1
):57
–65
. .22.
Rusch
VW
, Niedzwiecki
D
, Tao
Y
, Menendez-Botet
C
, Dnistrian
A
, Kelsen
D
, Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies
. J Clin Oncol
. 1992
;10
(6
):1001
–6
. .23.
Okabe
K
. Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma
. Ann Transl Med
. 2017
;5
(11
):233
. .24.
Richards
WG
, Zellos
L
, Bueno
R
, Jaklitsch
MT
, Jänne
PA
, Chirieac
LR
, Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma
. J Clin Oncol
. 2006
;24
(10
):1561
–7
. .25.
de Bree
E
, van Ruth
S
, Schotborgh
CE
, Baas
P
, Zoetmulder
FA
. Limited cardiotoxicity after extensive thoracic surgery and intraoperative hyperthermic intrathoracic chemotherapy with doxorubicin and cisplatin
. Ann Surg Oncol
. 2007
;14
(10
):3019
–26
. .26.
Ried
M
, Potzger
T
, Braune
N
, Neu
R
, Zausig
Y
, Schalke
B
, Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience
. Eur J Cardiothorac Surg
. 2013
;43
(4
):801
–7
. .27.
Ried
M
, Lehle
K
, Neu
R
, Diez
C
, Bednarski
P
, Sziklavari
Z
, Assessment of cisplatin concentration and depth of penetration in human lung tissue after hyperthermic exposure
. Eur J Cardiothorac Surg
. 2015
;47
(3
):563
–6
. .28.
Ried
M
, Potzger
T
, Braune
N
, Diez
C
, Neu
R
, Sziklavari
Z
, Local and systemic exposure of cisplatin during hyperthermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies
. J Surg Oncol
. 2013
;107
(7
):735
–40
. .29.
Zhao
ZY
, Zhao
SS
, Ren
M
, Liu
ZL
, Li
Z
, Yang
L
. Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis
. Oncotarget
. 2017
;8
(59
):100640
–7
. .30.
Hamilton
TD
, Taylor
EL
, Cannell
AJ
, McCart
JA
, Govindarajan
A
. Impact of major complications on patients’ quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
. Ann Surg Oncol
. 2016
;23
(9
):2946
–52
. .31.
Schwartz
RM
, Lieberman-Cribbin
W
, Wolf
A
, Flores
RM
, Taioli
E
. Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma
. BMC Cancer
. 2018
;18
(1
):1188
. .32.
Burkholder
D
, Hadi
D
, Kunnavakkam
R
, Kindler
H
, Todd
K
, Celauro
AD
, Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma
. Ann Thorac Surg
. 2015
;99
(5
):1775
–80
. .33.
Bolukbas
S
, Eberlein
M
, Schirren
J
. Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma
. J Thorac Oncol
. 2012
;7
(5
):900
–5
.© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
